Liver dysfunction was identified in a 16-year-old boy hospitalized with high fever and abdominal pain and fullness. He had received pharmacotherapy for a headache 2 months previously and other drugs for a high fever 4 days prior to being admitted to our hospital. The patient's liver dysfunction was consistent with and fulfilled the criteria for drug induced liver injury, but the laboratory findings showed elevated procalcitonin levels, hyponatremia and leukocytosis. Moreover, we confirmed the presence of human herpesvirus 6 (HHV-6) DNA. The patient exhibited symptoms of high fever and abdominal pain and fullness but no exanthema. The clinical and laboratory findings did not satisfy the criteria for drug-induced hypersensitivity syndrome, and we speculate that the diversity of clinical and laboratory findings may have resulted from HHV-6 reactivation. To the best of our knowledge, this is the first case report on drug-induced liver injury with various findings due to HHV-6 reactivation. HHV-6 reactivation should be considered in patients with drug induced liver injury even in the absence of exanthema.
Introduction
Human herpesvirus 6 (HHV-6) is a lymphotropic virus in the beta herpesvirus family. Primary infection occurs in most individuals within the first 2 years of childhood and results in exanthema subitum (1) . Primary HHV-6 infection is a lifelong infection and HHV-6 can be found in the peripheral blood, kidneys, salivary glands and central nervous system (2) .
HHV-6 reactivation does not typically result in significant morbidity in healthy individuals but has been associated with chronic fatigue syndrome (3), myocarditis (4) and drug-induced hypersensitivity syndrome (DIHS) (5, 6) . Liver dysfunction associated with HHV-6 reactivation is almost always eventually diagnosed as DIHS, for which exanthema is a major symptom (7) . We herein describe a case of druginduced liver injury with HHV-6 reactivation without exanthema.
Case Report
A 16-year-old boy had occasionally taken analgesics (acetaminophen, isopropylantipyrine and/or allylisopropylacetylurea) for headache relief 2 months prior and was subsequently treated with acetaminophen, maobushisaishinto, lysozyme hydrochloride, and cefcapene pivoxil hydrochloride for high fever and abdominal pain and fullness 4 days prior to being admitted to our hospital. Three days after, he was treated with clarithromycin, tranexamic acid, carbocysteine and ibuprofen for the same symptoms. The next day, the patient was referred to our hospital for symptoms of high fever and abdominal pain and fullness (Fig. 1) . He did not regularly consume alcohol and his family medical history was uneventful. On admission, the patient was alert and his body temperature was 39.2 . The conjunctivae were not jaundiced, and heart and respiratory sounds were normal. No abnormalities were identified in the chest or on the skin. Furthermore, there was no lymph node enlargement or joint swelling throughout the whole body. The patient's abdomen was slightly hard and showed tenderness in the epigastric re- gion without peritoneal irritation sign. On admission, the laboratory findings revealed severe liver dysfunction (AST: 1,104 IU/L; ALT: 1,979 IU/L) and inflammatory status (white blood cell: 21,400/μL; CRP: 3.98 mg/dL). Moreover, the laboratory findings indicated elevated procalcitonin levels, hyponatremia and leukocytosis (Table) . An abdominal computed tomography showed periportal edema, thickening of the gallbladder wall, pleural effusion, ascites and irregular enhancement of the liver (Fig. 2) . A biopsy of the liver showed bridging perivenular necrosis and infiltration of lymphocytes and eosinophils (Fig. 3) .
The lymphocyte stimulation testing for acetaminophen was positive, and according to the criteria for drug-induced liver injury (DILI) (8), the score for our patient was 10, in- dicating a high probability of DILI. Almost all the clinical findings suggested a diagnosis of DILI due to acetaminophen, but the symptoms of pleural effusion, elevated procalcitonin levels and hyponatremia were atypical for drug-related liver failure.
We discontinued all drugs the patient was taking prior to admission at our hospital. After receiving treatment with neo-minophagen C, cefmetazole and thrombomodulin, the pleural and pericardial effusions rapidly diminished, and the patient's liver enzyme levels normalized.
Discussion
DILI is a major cause of acute liver injury and may induce serious liver injury. The causal drugs in DILI vary, and reports of DILI associated with dietary supplements and Chinese herbal drugs have recently increased (9). Although our patient had received treatment with numerous drugs before admission to our hospital, acetaminophen was suspected as the most likely causal agent based on the clinical course, such as repeated doses and receiving the highest score possible on the criteria for DILI (8) , although it is possible that other drugs could be the causal agent. Acetaminophen is well-known as a cause of DILI, inducing liver damage through its metabolite N-acetyl-p-benzoquinone imine (10) .
The clinical presentation of DILI varies, ranging from an asymptomatic elevation of the hepatic enzyme levels to fulminant hepatic failure. General malaise is the most frequent symptom, followed by jaundice, anorexia, fever, nausea, pruritus and subsequent skin rash (9) . Conversely, symptoms such as marked ascites, pleural effusion and hyponatremia were difficult to explain by DILI alone in the present case although the liver damage was severe. Moreover, the patient had an elevated level of procalcitonin despite negative findings for all laboratory cultures.
These findings required us to consider other potential causes affecting the clinical presentation in the present case. We therefore checked for and confirmed HHV-6 reactivation. HHV-6 reactivation is an integral part of DIHS (6, 7) and a severe drug-induced adverse reaction. The diagnosis of typical DIHS can be confirmed if the following 7 criteria are fulfilled: 1) maculopapular rash developing after administration of the specific causative drug; 2) prolonged clinical symptoms; 3) fever >38 ; 4) liver dysfunction; 5) leukocytosis, atypical lymphocytosis and eosinophilia; 6) lymphadenopathy; and 7) HHV-6 reactivation. The presence of 5/7 criteria is indicative of atypical DIHS (10) .
Drugs commonly associated with DIHS include antiepileptic drugs, diaphenylsulfone, allopurinol, minocycline and mexiletine (10) . One case of suspected DIHS associated with acetaminophen has been previously reported (11) . The present case did not satisfy the criteria for DIHS due to the absence of rash. Thus, the present case is worthy of reporting because DILI with diverse findings due to HHV-6 reactivation is rarely seen. DIHS may be accompanied by numerous systemic complications, including encephalitis, pneumonitis, pancreatitis, eosinophilic colitis or esophagitis and myocarditis (7, 12, 13) . HHV-6 reactivation is one criterion for DIHS, and severe liver dysfunction in DHIS is more frequent with HHV-6 reactivation than without (14) . Moreover, a relapse of high fever and liver dysfunction is also more frequent with HHV-6 reactivation than without. HHV-6 reactivation may have also induced diverse symptoms in our patient. In fact, some reports have described HHV-6 reactivation after drug administration inducing marked pleural effusion, ascites and hyponatremia (15) (16) (17) . The elevation of procalcitonin levels has likewise been described in patients with drug reactions with eosinophilia and systemic symptoms (DRESS) and has been considered similar to DIHS (18) .
Regulatory T-cells proliferate during the acute phase of DIHS and may suppress anti-viral immune responses, resulting in the induction of HHV-6 reactivation (12, 19) . Therefore, T-cell activation by drugs and following HHV-6 reactivation may explain DILI as the main cause of liver dysfunction in the present patient and HHV-6 reactivation may merely be a coexisting pathological condition. Alternatively, HHV-6 has been shown to induce the production of inflammatory cytokines such as tumor necrosis factor α, interferon-γ, interleukin (IL)-2 and IL-4 (20) (21) (22) . Such reactions may also explain some of the clinical manifestations previously reported (23) , although the mechanisms linking HHV-6 reactivation to various symptoms remain unclear.
The standard treatment for DIHS is moderate-or highdose corticosteroids (7) . In addition to high-dose prednisolone (PSL) therapy, high-dose intravenous immunoglobulin therapy has also been reported in severe DIHS (24) . HHV-6 reactivation is usually temporary, requiring no therapeutic intervention. However, the presence of HHV-6 reactivation is associated with increased severity of DIHS and poorer prognosis, so ganciclovir treatment should be considered (11) . Fortunately, the patient in this case improved without corticosteroid or ganciclovir treatment, which may also suggest that this case was not representative of DIHS.
In conclusion, HHV-6 reactivation should therefore be taken into account for patients with drug induced liver injury, regardless of the presence or absence of exanthema. If HHV-6 is found to be present, close monitoring of the symptoms or laboratory findings and proper treatment is essential to prevent the progression to liver failure. Furthermore, corticosteroids or ganciclovir treatment should be considered in patients suspected to have DIHS.
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